Loading
A phase 3 trial of Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection is a phase 3 interventional study registered as NCT05120349 by AstraZeneca, with 390 participants enrolled, started 2022-02-21 and due to reach its primary completion in 2027-08-02. Interventions recorded: Osimertinib, Placebo. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/